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OBJECTIVE: To analyze steroidogenesis-related gene expression in the rat ovary exposed to melatonin
supplementation.
METHODS: Thirty-two virgin adult female rats were randomized to two groups as follows: the control group GI
received vehicle and the experimental group GII received melatonin supplementation (10 mg/night per animal)
for 60 consecutive days. After the treatment, animals were anesthetized and the collected ovaries were
immediately placed in liquid nitrogen for complementary deoxyribonucleic acid microarray analyses. A
GeneChipH Kit Rat Genome 230 2.0 Affymetrix Array was used for gene analysis and the experiment was
repeated three times for each group. The results were normalized with the GeneChipH Operating Software
program and confirmed through analysis with the secondary deoxyribonucleic acid-Chip Analyzer (dChip)
software. The data were confirmed by real-time reverse transcription polymerase chain reaction analysis. Genes
related to ovarian function were further confirmed by immunohistochemistry.
RESULTS: We found the upregulation of the type 9 adenylate cyclase and inhibin beta B genes and the
downregulation of the cyclic adenosine monophosphate response element modulator and cytochrome P450
family 17a1 genes in the ovarian tissue of GII compared to those of the control group.
CONCLUSION: Our data suggest that melatonin supplementation decreases gene expression of cyclic adenosine
monophosphate, which changes ovarian steroidogenesis.
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& INTRODUCTION
In rats and in humans, there is evidence of direct
melatonin action on ovarian function, steroidogenesis
modulation (1,2), primarily during progesterone production
(3). In addition, high concentrations of the hormone are
found in the preovulatory follicular fluid (4) and associated
with the type I (MT1) and type II (MT2) melatonin receptors
in rat and human ovarian follicles (5).
Melatonin levels may influence the physiological and
neoplastic processes of the reproductive system. Women
with neoplastic proliferative activity are known to have
much lower than normal melatonin levels (6), suggesting an
association between neoplastic growth and melatonin. This
is the reason many authors have investigated the molecular
mechanism of indoleamine action and tested melatonin in
the adjuvant treatment of estrogen-dependent malignant
tumors in the female genital system (6). However, high
melatonin levels were found in endocrine disorders, such as
polycystic ovary syndrome (PCOS) (7). These findings
suggest that melatonin exerts an influence on the behavior
of the genital system, especially the gonads. Voordouw et al.
(7) found that melatonin in association with progestogen
acted on the inhibition of ovarian function without affecting
the sleep-wake rhythm. The authors suggested employing
melatonin for human contraception.
Melatonin has been hypothesized to have the requisites
for consideration as an antiestrogenic drug due to its
interference with estrogen receptors (8). Additionally,
melatonin acts on estrogen synthesis via the inhibition of
enzymes (aromatases) that control its interconversion from
androgen precursors (8). However, the action of melatonin
depends on serum estrogen levels (9).
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Experimentally, melatonin acts on the malignant tumors
of the reproductive system, especially those that are
estrogen dependent. In fact, patients exhibiting tumoral
activity have lower than normal melatonin levels. This fact
seems to indicate that the production of indoleamine is
connected with tumor development. However, the exact
mechanisms involved in the action of melatonin on tumor
cells are not known (10,11). In addition, women with PCOS
have elevated serum melatonin levels (12). Again, the
reason for or mechanism involved in this increase is still
elusive. In granulosa cell cultures, melatonin receptor
expression is dependent on steroid levels, particularly on
androgen levels. Thus, there is clear interference of the sex
steroids in the function of melatonin in the ovary (13).
Prata Lima et al. (14) showed that a reduction in melatonin
levels in rats may trigger the development of micropolycystic
ovaries. Soares Jr et al. (15) detected an increase in the
number of interstitial cells and proliferation of the theca
interna of the ovarian follicle. These changes are similar to
those observed in the ovaries of women presenting anovula-
tion with hyperandrogenism. Furthermore, pinealectomized
animals exhibited a reduction in fertility with a decrease in
oocytes during ovulation (16). Melatonin replacement, how-
ever, diminishes the number of cysts in rat ovaries, probably
due to melatonin’s antigonadotropic effects (17). Moreover,
rats that underwent surgery for pineal gland removal
developed histological signs suggestive of endometrial
hyperplasia, which was also reversed by the use of melatonin
(16). In addition, melatonin may decrease estrogen expres-
sion in endometrial tissue (18).
Melatonin may have an antiproliferative effect and it acts
on the reproductive system (19); therefore, it is essential to
search for ovarian proliferation signals and the enzymes
that interfere with steroidogenesis. In fact, these goals led us
to observe the effect of melatonin supplementation on
ovarian gene expression in normal rats, including steroido-
genic and ovarian proliferation enzymes.
& MATERIAL AND METHODS
Animals
Thirty virgin adult (three-month-old) female EPM-1
Wistar rats (Rattus norvegicus albinus), weighing approxi-
mately 200 g each, were used in this study. They were
housed in plastic cages with metal grids and kept on
standard rat chow (Labina Purina, Brazil) and water ad
libitum at a room temperature of 22 C˚. Lighting was
artificial and provided by 40-watt daylight fluorescent
lamps (Philips, Brazil) placed in a carefully dimensioned
and well-ventilated wooden box. The lamps supplied
approximately 400 lux in the area occupied by the rats in
a light-10:dark-14 photoperiodic cycle (lights on from 8 a.m.
to 6 p.m.) throughout the experiment. This study was
approved by the local ethics committee (N˚ 0233/06). The
procedures met the criteria for the care and management of
experimental animals.
Daily samples of vaginal secretions were taken to assess
ovarian function. Only rats with regular estrous cycles were
included in the study.
The rats (n = 32) were randomized to two groups: GI,
control, received vehicle and GII, experimental, received
melatonin supplementation (10 mg/night per animal) for 60
consecutive days.
Vaginal cytological examination
Following a two-week period of adjustment to the new
environment, all animals were subjected to daily collection
of vaginal secretions for four consecutive weeks. The
material was processed and stained by the Harris-Shorr
method. Only the rats with regular estrous cycles were
included. Samples were also collected throughout the study
to identify the estrous cycle.
Melatonin supplementation
Melatonin (Sigma Chemical Co., St. Louis, USA) was
dissolved in ethyl alcohol and then in drinking water (final
concentration: 0.4 mg/mL); it was then poured into amber
bottles and made available to the animals during the dark
period (6 p.m. to 8 a.m.). The intake dose of melatonin was
calculated to be approximately 10 mg/night per animal.
Access to water was restricted during the light period (8 a.m.
to 6 p.m.). For GI, the same amount of ethanol was added to
the drinking water.
Organ excision
All animals in proestrous were anesthetized intraperito-
neally with 15 mg/kg of xylazine (RompunH) and 30 mg/
kg of ketamine (KetalarH). The ovaries were removed and
maintained at -80 C˚ for subsequent molecular biology
analysis followed by immunohistochemical analysis. The
animals that were not in proestrous continued to receive the
same treatment (vehicle or melatonin according to their
groups) and were euthanized upon reaching proestrous.
Isolation, synthesis and labeling of complementary
RNA
Total RNA was extracted from ovarian tissue with TrizolH
reagent (Invitrogen) according to the manufacturer’s
instructions. Following total RNA extraction, the sample
was purified with the Qiagen RNeasy Mini Kit (USA)
according to the manufacturer’s instructions and RNA
integrity was checked in 1% agarose gels to evaluate the
ribosomal band integrity and quantified with a spectro-
photometer.
Total RNA (3 micrograms) from the tissue of interest was
first converted into complementary DNA (cDNA). The final
product of the cDNA synthesis reaction was purified with
the GeneChip Sample Cleanup Module System (Affymetrix,
Santa Clara, CA); the manufacturer’s instructions were
strictly followed.
The cDNA was transcribed in vitro to biotinylated
complementary RNA (cRNA) by incorporating biotin-CTP
and biotin-UTP using the Affymetrix IVT labeling kit (One-
Cycle Target Labeling Kit; Santa Clara, CA). A sample of
15 mg of biotin-labeled RNA was generated and then
fragmented to a 200 bp size by incubation in fragmentation
buffer for 35 minutes at 94 C˚ prior to overnight hybridiza-
tion. Fragmented RNA was assessed for its relative length in
1% agarose gels. A solution prepared with a hybridization
reagent from the GeneChip Hybridization Wash and Stain
Kit (Affymetrix) was added to the fragmented cRNA. The
resultant solution was placed in the GeneChip Rat 230 2.0
Array chip, which in turn was placed in a hybridization
oven at 45 C˚ and hybridized for 16 hours at 60 rpm.
The RNA processing and microarray protocols were carried
out in the Molecular Core-Microarray Facility in Sa˜o Paulo,
Brazil.
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After hybridization, the chip was placed in the washing
and coloring station of the fluidics station (GeneChip
Fluidics Station 400; Affymetrix), in which the excess
nonhybridized oligonucleotides were retrieved from the
chip and cRNA was labeled with biotin. Once effectively
connected to the chip probes, biotin was labeled with a
solution containing fluorescence-conjugated streptavidin.
Afterward, the chip was analyzed using the GeneChip
Scanner 3000 7G connected to the GeneChip Operating
Software (Affymetrix). Sign quantification allows the
expression of thousands of genes to be compared under
various experimental conditions. All samples were analyzed
in triplicate. Images were captured, the initial analysis of
hybridizations was performed with MicroArray Suite 5.0
(Affymetrix) software and the generated files were saved in
the cell format.
Quantitative real-time polymerase chain reaction
(qRT-PCR)
Additionally, we conducted qRT-PCR to confirm the data.
The resultant cDNAs underwent conventional PCR using a
pair of specific primers for the b-actin gene (S: 59-CGAGG-
CCCAGAGCAAGAGAG-39; AS: 59-AGGAAGAGGATGC-
GGCAGTGG-39; GenBank accession number NM_031144.2)
to verify the effectiveness of synthesis. Following fragment
analysis in agarose gels (Invitrogen), the cDNAs were
subjected to qRT-PCR reactions. The oligonucleotides for
amplification were the following:
ADCY9 (S: 59-CAGTGCGGTGGTGGAAAAA-39; AS: 59-
CAGCGACCTCTGCCAACCT-39); INHBB (S: 59-TCCTAGT-
GCCCTGCTGAGAT-39; AS: 59-ACCCACAGGGACAACTT-
CTG-39); CREM (S: 59-AGTCCCCAGCAACTAGCAGA-39;
AS: 59-CACAGTCAACCAGGTCCAA-39); and CYP17A1 (S:
59-ACTGAGGGTATCGTGGATGC-39; AS: 59-TCGAACTT-
CTCCCTGCACTT-39).
All of the primers were designed using the Primer
Express 3.0 (Applied Biosystems, Foster City, CA, USA)
program and synthesized by integrated DNA technology
(DNA Technologies, Coralville, IA, USA). Reactions were
carried out in duplicate with the 7500 Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA) using a
total volume of 25 ml with 450 nM of primers and SYBR
Green PCR Master Mix (Applied Biosystems). Fluorescence
intensity was measured at the end of the extension phase of
each cycle. Relative expression (R) was calculated using the
equation R = 22[DCT sample 2 DCT control]. To determine a
normalized arbitrary value for each gene, each data point
was normalized to the control gene (b-actin) and to its
respective controls (20).
Immunohistochemical analysis
All of the ovary samples investigated in the study were
tested using the primary goat polyclonal antibodies anti-
Per2 against the clock gene Period 2 (15200; Santa Cruz
Biotechnology, USA; H-90; sc-25363); anti-Cyp17a1 (15200;
Santa Cruz Biotechnology, USA; C-17; sc-46081); and anti-
Cyp19a1 (15200; Santa Cruz Biotechnology, USA; H-18; sc-
14244) and then incubated with the second antibody and
with secondary antibodies from a Dako kit (Dako LSAB +
Sys, Peroxidase Universal K0690-1). After 30 minutes of
incubation followed by washing, the sections were again
incubated with a freshly prepared solution of streptavidin-
biotin immunoperoxidase (Dako LSAB kit) according to the
manufacturer’s protocol. After washing, the bound enzyme
was visualized following one additional incubation with the
enzyme in the presence of 1% 3, 39-diaminobenzidine
tetrahydrochloride (Dako K3468-1). Bovine serum albumin
replaced the primary antibody and was used as a negative
control. Other negative controls were applied using non-
specific goat antibodies with the same concentration as that of
the primary antibody for each immunohistochemical reaction
(Per2, Cyp17a1 and Cyp19a1) and for staining the sections
with hematoxylin. Afterwards, the image was analyzed using
AxioVision (Carl Zeiss) and expression was quantified
according to the color intensity in the field. The intensity of
the immunoreactions was classified according to proposed
criteria that included negative-zero, weak-1, moderate-2,
strong/intense-3, or intense-4 (21). Three experienced obser-
vers who were blinded to the purpose of the slides carried
out all of the assessments. After completion of the study, the
same observers reexamined the slides to ensure reproduci-
bility of the semiquantitative assessment.
Statistical methods
To analyze the microarray technique statistically, the data
were normalized using the Robust Multi-Array Average
(RMA) method. The differentially expressed genes (DEGs)
were selected using two distinct methods: Limma and
RankProd. Both had p-value,0.05 adjusted for the false
discovery rate (FDR) to obtain the significance level.
Comparative analyses were performed to identify the
differentially expressed genes under distinct experimental
conditions; the genes were grouped according to their
expression levels and categorized according to their
biological functions.
Analysis of variance (ANOVA), along with the post-hoc
Tukey test, was used to compare the 6-sulfatoxymelatonin
results and those of the immunohistochemical analyses.
Differences were considered significant at the p,0.05 level.
Data are expressed as the mean ¡ SEM. All statistical tests
were performed using GraphPad Prism version 5.0 for
Windows (GraphPad Software, San Diego, CA). The power
calculation was based on the previous data from Lombardi
et al. (22).
& RESULTS
Estrous cycles
Vaginal cytology showed estrous cycles lasting from 4 to 5
days in the control group animals (GI). In the experimental
group (GII, melatonin supplementation), most animals had
4- to 6-day cycles.
Microarray analysis
Of the 31,100 genes that underwent transcriptional
analysis, 835 had a known biological function. A total of
416 genes were transcribed and differentially expressed in
the two groups. Of these 416 genes, 279 were expressed less
in GII (melatonin supplementation) than in GI (treatment
with vehicle). The genes with at least a two-fold increase
(upregulation) or a two-fold decrease (downregulation)
relative to GII were considered significant in terms of
known ovarian function. The genes are listed in Table 1.
Table 1 displays a summary of the genes that were
selected. Using the microarray technique and confirming
the results using the qRT-PCR technique, differences were
found between GI and GII with respect to the following
genes: type 9 adenylate cyclase (ADCY9), inhibin beta B
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(INHBB), cyclic AMP responsive element modulator
(CREM) and cytochrome P450 family 17a1 (CYP17A1). The
former two genes were upregulated and the latter two were
downregulated relative to control.
Genes expressed by the qRT-PCR analysis
The qRT-PCR results were obtained using the same
samples included in the microarray experiment. We selected
the ADCY9, INHBB, CREM and CYP17A1 genes.
There were no significant difference between the two
groups with respect to INHBB (p= 0.20). The ADCY9 gene
was more highly expressed in the group with melatonin
supplementation (GII) than in the control group (GI)
(p,0.01). The opposite was true for the CREM and
CYP17A1 genes, which were less expressed in GII than in
GI (p,0.01). The data are shown in Figures 1A, B, C and D.
Immunohistochemical analysis
Per2 reactivity was more highly expressed not only in the
granulosa cells of the ovarian follicle and the blood vessels
of the ovarian stroma but also in theca interna cells and
interstitial cells in the group with melatonin supplementa-
tion (GII) (p,0.05). Cyp17a1 also showed greater expression
in the theca interna cells and the granulosa cells in the
control group (GI) than in the experimental group (GII)
(p,0.05). There was no difference between the groups with
respect to Cyp19a1 (Table 2 and Figure 2).
& DISCUSSION
In the United States, melatonin sales are not under
government control and the hormone is sold as a dietary
supplement to be taken in daily doses of 0.5 to 50 mg. There
are no reports in the literature of severe side effects
associated with melatonin intake (23). A few authors report
cephalgia, nausea and an overall feeling of being unwell
following higher doses (24). However, little is known about
melatonin’s effects on the reproductive system, particularly
in women with normal melatonin levels. Consequently, our
study aimed to evaluate the potential influence of melatonin
supplementation on animals that were not manipulated
surgically to assess the interference of the hormone with the
female reproductive system, particularly the ovaries.
Our results showed that melatonin may increase cyclin
gene expression, especially type 9 and decrease the
production of CREM, which acts on the cyclic AMP
pathway. Concomitantly, we found that melatonin acts on
the enzymes involved in steroidogenesis via a decrease in
CREM (25). It should be noted that this gene represses
CYP17A1 expression (25). Therefore, melatonin may control
ovarian function through its influence on the enzymes of
steroidogenesis.
The CYP17A1 family may play a role in cortisol production
in humans and in that of corticosterone in rodents, thus
establishing a difference between these species, but they are
also important in androgen production. In addition, the
expression of these genes exhibits circadian variation both in
rodents and in humans (26). At this point, melatonin may
influence expression via CREM (27,28). Our data suggest that
melatonin supplementation alters expression of this hormone
by inducing changes in ovarian steroidogenesis (27).
Ovarian steroidogenesis generally depends on the inter-
action between two specialized cells (internal thecae and
granulosa cells) that are important for follicular develop-
ment and ovulation (19,29). In fact, androgen is synthesized
from cholesterol in thecal cells in response to luteinizing
hormone (LH) and then subsequently converted to estro-
gen in granulosa cells through the action of follicle-
stimulating hormone (FSH). The LH receptor and the
Cyp17a1 enzyme, which converts pregnenolone and
progesterone into dehydroepiandrosterone (DHEA) and
androstenedione, are expressed primarily in theca interna
cells and the FSH receptor and aromatase (CYP19A1) are
expressed in granulosa cells, where androgens are converted
into estrogens (27). Curiously, the LH receptor is also
expressed in the external portion of the granulosa in response
Table 1 - List of upregulated and downregulated genes in GI (control, treatment with vehicle) relative to GII
(experimental, melatonin supplementation).
Upregulated genes Symbols R
Epoxide hydrolase 2, cytosolic EPHX2 q 2.950
FC Fragment of IgE, Low Affinity II, Receptor For FCER2 q 2.860
Aldehyde Dehydrogenase Family 1, Subfamily A7 ALDH1A7 q 2.820
Cbp/p300-interacting transactivator 1 CITED1 q 2.820
Adenylate cyclase type 9 ADCY9 q 2.560
Inhibin, beta B INHBB q 2.510
LIM domain 7 LMO7 q 2.300
Paraspeckle protein 1 PSPC1 q 2.280
Plasma membrane calcium-transporting ATPase 1 ATP2B1 q 2.190
Potassium voltage-gated channel subfamily D member 3 KCND3 q 2.160
Downregulated genes Symbols R
Epiregulin EREG Q 18.918
Nuclear receptor subfamily 4, group A, member 3 NR4A3 Q 10.157
Amphiregulin AREG Q 9.181
Sulfiredoxin-1 SRXN1 Q 7.046
Seminal vesicle secretory protein 5 SVS5 Q 6.841
Tumor necrosis factor, alpha-induced protein 6 TNFAIP6 Q 6.472
cAMP responsive element modulator CREM Q 6,446
Cytokine-inducible SH2-containing protein CISH- Q 6,249
Cytochrome P450 17A1 CYP17A1 Q 6,135
Cysteine-serine-rich nuclear protein 3 CSRNP3 Q 6.073
Glutamyl-prolyl-tRNA synthetase EPRS Q 5.826
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to FSH before LH appears. It should be emphasized that
melatonin may both influence LH release through the
hypophysis and interfere with the effect of LH on the ovary
(19,29).
The FSH and LH receptors are coupled with the
stimulatory G protein acting on cyclic AMP and upon
activation of its ligand, they stimulate adenyl cyclase, which
generates an intracellular increase in cyclic AMP and
subsequent activation of protein kinase A (PKA). The
increase in cyclic AMP promotes steroidogenesis and not
only raises StAR expression but also increases its activity
through serine phosphorylation. In addition, cyclic AMP
regulates other important proteins in steroidogenesis, such
as Cyp19a1 (aromatase) and Cyp17a1 in the granulosa and
theca interna cells, respectively (30).
Activation of the subunits coupled with the G protein
activate Src, which triggers the Ras/Raf/MEK/MAPK/ERK
pathway. LH and FSH stimulation may increase the activity
of extranuclear signal-regulated kinase (ERK), which
subsequently raises StAR expression in some tissues, such
as the adrenal glands. However, Src and MAPK signaling in
theca interna cell cultures leads to the inhibition of steroid
production and reduces the activity of Cyp17a1 and other
enzymes (31). Melatonin supplementation appears to exert
an effect that is opposed to that of the gonadotropic
receptors, with a decrease in CREM and an increase in
CYP17A1, as our data show.
It should be emphasized that melatonin may become
involved in ovarian function indirectly through changes in
the gonadotropins (29) or directly in the ovary via activation
of its type I or type II receptor (31). The Chinese hamster
ovary has been used to study physiological activation of the
melatonin receptor (MT1), which potentiates several points
of the signal transduction cascade mediated by cyclic AMP
(cyclic adenosine monophosphate), by protein G activation,
by protein kinase A (PKA) activation and by phosphoryla-
tion of the transcription factor of the protein that binds to
the element responsive to cyclic AMP (CREB). The
phosphorylation that binds CREB through kinase A is a
critical step for promoting DNA transcription and it may
reduce CREM concomitantly. It is worth noting that this
mechanism is the main mechanism conveying information
from the melatonin photoperiod to the body and its action is
dependent on high levels of nocturnal melatonin (32).
Figure 1 - Values of ADCY9, INHBB, CREM and CYP17A1 gene expression relative to b-actin. A – Mean and standard deviation of 2-DDCt
from the qRT-PCR of the ADCY9 gene between GI and GII, using the same samples included in the microarray experiments (ADCY9,
*p,0.01 compared to GI). B – Mean and standard deviation of 2-DDCt from the qRT-PCR of the INHBB gene between GI and GII using
the same samples included in the microarray experiments. No difference was detected (INHBB, p=0.20). C – Mean and standard
deviation of 2-DDCt from the qRT-PCR of the CREM gene between GI and GII, using the same samples included in the microarray
experiments (CREM, *p,0.01 compared to GI). D – Mean and standard deviation of 2-DDCt from the qRT-PCR of the CYP17A1 gene
between GI and GII, using the same samples included in the microarray experiments (CYP17A1, *p,0.01 compared to GI). ADCY9:
adenylate cyclase 9; INHBB: inhibin beta B; CYP17A1: 17-alpha-monooxygenase; CREM: cyclic adenosine monophosphate responsive
element modulator.
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In ovarian function, the cyclic AMP signaling pathway is
involved in many aspects of the differentiation, maturation
and function of granulosa cells in ovarian follicles (33). In
the ovary, theca interna cells, when completely differen-
tiated, exhibit ultrastructural features of steroid-producing
cells. The theca interna cells synthesize androstenedione,
which is transported to the granulosa cells and acts under
the influence of FSH to synthesize the aromatase enzyme,
which transforms androstenedione into estrogen (34). It
should be noted that the rise in cyclic AMP is closely related
to an increase in steroidogenesis in the granulosa cells due
to the increased activity of aromatase cytochrome 450,
which converts androgens into estrogens (32). Melatonin
may have a modulatory effect on steroidogenesis because
when the melatonin receptor is activated, there is a drop in
cyclic AMP in the granulosa cells in vitro (31). Moreover,
melatonin may trigger other cell mechanisms in the ovarian
tissue as it interferes in steroidogenesis. Our data based on
normal animals show that melatonin may also diminish
CREM production, which may be a repressor of gene
activation when the activator is cyclic AMP and would
explain characterization of the Cyp17a1 enzymes (30).
Table 2 - Mean and standard deviation from the mean of
Per2 (period circadian clock 2), Cyp17a1 (17-alpha-
monooxygenase), and Cyp19a1 (aromatase) expression
measurements by immunohistochemistry in GI (vehicle)
and GII (melatonin supplementation).
GI (Vehicle) GII (Melatonin)
Per2
Theca interna cells 1.50¡0.02 2.30¡1.01*
Granulosa cells 1.50¡0.03 3.10¡0.04*
Interstitial cells 1.50¡0.01 2.30¡0.45*
Cyp17a1
Theca interna cells 1.80¡0.01 2.90¡0.01*
Granulosa cells 0.21¡0.11 0.17¡0.23
Interstitial cells 0.28¡0.82 0.11¡0.13
Cyp19a1
Theca interna cells 0.05¡0.01 0.06¡0.01
Granulosa cells 1.81¡0.19 1.87¡0.21
Interstitial cells 0.16¡0.42 0.15¡0.73
*p,0.05 compared to GI.
Figure 2 - Photomicrographs of ovarian sections after immunostaining. Expression of Per2 (period circadian clock 2), Cyp17a1 (17-alpha-
monooxygenase) and Cyp19a1 (aromatase). GI: control group; GII: experimental group (received melatonin supplementation). Note
the greater expression of Per2 in the theca interna cells (arrows) compared to the granulosa cells (CG) and interstitial cells in GII relative
to GI. Please also note the intense reactivity for Cyp17a1 in the theca interna (arrows) and granulosa cells (CG) in the GI. Bar = 20 mm,
400 X.
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There is some evidence that inhibin expression depends
on the pathways of both protein kinase A (PKA) (35) and/or
protein kinase C (PKC) (36), as well as on FSH and LH
action on the PKA pathway (37); our data also suggest
melatonin participation. Physiologically, during follicular
growth, high LH concentrations increase the activity of the
PKA pathway and activate PKC and they also diminish
aromatase activity in rat granulosa cell cultures (38).
Melatonin may not exert a strong influence on inhibin B
as indicated by real-time PCR and according to our data.
However, further studies are necessary to ensure that
melatonin does not influence on this pathway.
In short, our study shows that there are molecular
alterations in the ovary brought about by changes in
steroidogenesis-associated gene expression after melatonin
supplementation with an intact pineal. The important point
of this study is that melatonin had an impact on ovarian
function through Cyp17a1. In clinical practice, melatonin
sold as a supplement may influence the reproductive
system. Therefore, melatonin should be prescribed with
attention to specific melatonin-deficiency symptoms and not
to all patients due to its influence on ovarian function.
However, our study did not address the repercussions for
fertility and pregnancy of these animals, which was a
limitation of our study. Consequently, further studies are
necessary.
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